Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease
Open Access
- 14 August 2015
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (8) , 977-989
Abstract
Background The impact of early treatment with immunomodulators (IM) and/or TNF antagonists on bowel damage in Crohn's disease (CD) patients is unknown. Aim To assess whether ‘early treatment’ with IM and/or TNF antagonists, defined as treatment within a 2‐year period from the date of CD diagnosis, was associated with development of lesser number of disease complications when compared to ‘late treatment’, which was defined as treatment initiation after >2 years from the time of CD diagnosis. Methods Data from the Swiss IBD Cohort Study were analysed. The following outcomes were assessed using Cox proportional hazard modelling: bowel strictures, perianal fistulas, internal fistulas, intestinal surgery, perianal surgery and any of the aforementioned complications. Results The ‘early treatment’ group of 292 CD patients was compared to the ‘late treatment’ group of 248 CD patients. We found that ‘early treatment’ with IM or TNF antagonists alone was associated with reduced risk of bowel strictures [hazard ratio (HR) 0.496, P = 0.004 for IM; HR 0.276, P = 0.018 for TNF antagonists]. Furthermore, ‘early treatment’ with IM was associated with reduced risk of undergoing intestinal surgery (HR 0.322, P = 0.005), and perianal surgery (HR 0.361, P = 0.042), as well as developing any complication (HR 0.567, P = 0.006). Conclusions Treatment with immunomodulators or TNF antagonists within the first 2 years of CD diagnosis was associated with reduced risk of developing bowel strictures, when compared to initiating these drugs >2 years after diagnosis. Furthermore, early immunomodulators treatment was associated with reduced risk of intestinal surgery, perianal surgery and any complication.Keywords
Funding Information
- Swiss National Science Foundation (33CSC0_160115/1, 32003B_135664/1, 310030-120312, 320000-114009/3, 32473B_135694/1)
- MSD Merck Sharp & Dohme AG Switzerland
- Tillotts Pharma AG Switzerland
- Takeda AG Switzerland
- Otsuka AG Switzerland
- University of Zurich
This publication has 23 references indexed in Scilit:
- Surgery in a Population-Based Cohort of Crohn's Disease From Olmsted County, Minnesota (1970–2004)American Journal of Gastroenterology, 2012
- Development of the Crohnʼs disease digestive damage score, the Lémann scoreInflammatory Bowel Diseases, 2011
- Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based CohortGastroenterology, 2010
- Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection ratesGut, 2010
- Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial DataAmerican Journal of Gastroenterology, 2010
- Early Crohn disease: a proposed definition for use in disease-modification trialsGut, 2010
- Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and healthInflammatory Bowel Diseases, 2010
- Cohort Profile: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)International Journal of Epidemiology, 2008
- Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgeryGut, 2005
- Long-Term Evolution of Disease Behavior of Crohn's DiseaseInflammatory Bowel Diseases, 2002